These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23606708)

  • 1. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
    Saadoun D; Resche Rigon M; Thibault V; Longuet M; Pol S; Blanc F; Pialoux G; Karras A; Bazin-Karra D; Cazorla C; Vittecoq D; Musset L; Decaux O; Ziza JM; Lambotte O; Cacoub P
    Ann Rheum Dis; 2014 May; 73(5):831-7. PubMed ID: 23606708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
    J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
    Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
    J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
    Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M; Pol S; Mallolas J; Fainboim H; Cooper C; Slim J; Rivero A; Mak C; Thompson S; Howe AY; Wenning L; Sklar P; Wahl J; Greaves W;
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
    Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
    Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
    Milazzo L; Falvella FS; Magni C; Gervasoni C; Peri AM; Cattaneo D; Antinori S; Vidale S
    Pharmacology; 2013; 92(5-6):235-7. PubMed ID: 24192929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
    Hayashi N; Okanoue T; Tsubouchi H; Toyota J; Chayama K; Kumada H
    J Viral Hepat; 2012 Feb; 19(2):e134-42. PubMed ID: 22239511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.
    Chachá SGF; Rodrigues JPV; Araújo RC; Pereira LRL; Villanova MG; Souza FF; Santana RC; Martinelli ALC
    Rev Soc Bras Med Trop; 2018; 51(2):146-154. PubMed ID: 29768546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
    Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
    Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
    Montes ML; Nelson M; Girard PM; Sasadeusz J; Horban A; Grinsztejn B; Zakharova N; Rivero A; Durant J; Ortega-Gonzalez E; Lathouwers E; Janssen K; Ouwerkerk-Mahadevan S; Witek J; González-García J
    J Antimicrob Chemother; 2016 Jan; 71(1):244-50. PubMed ID: 26483516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.